IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

GSK may cut up to 1,217 jobs in Belgium amid vaccine demand shift — 15hGSK may cut up to 1,217 permanent jobs in Belgium—about 14% of its workforce there—in a global restructuring targeting £1.9 billion in savings by 2029.

+3

Dana Whitfield These cuts will hit many middle managers hard after years of building up vaccine capacity in Belgium.

GSK plans $800M Montgomery County expansion, 300 jobsHealth — 5dGSK will invest more than $800 million at Upper Merion Township, adding over 300 jobs; Shapiro and Siger announced the expansion Oct. 9, 2026.

0

GSK earns FDA approval for Jideytro — Jul 23, 2026GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.

0

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B — Sep 3, 2026GSK agreed to license Hutchmed’s HMPL-A830, a KRAS-EGFR antibody-drug conjugate, for up to $1.295 billion including $110 million upfront, with global rights outside Mainland China, Hong Kong, Macau and Taiwan while Hutchmed retains development and commercialization duties in those regions. The collaboration targets initial trials in colorectal, pancreatic, and lung cancers, leveraging a dual KRAS-EGFR mechanism to improve efficacy and tolerability.

+2

Jared Kim Dual-targeting KRAS-EGFR is an interesting bet, hope it actually improves tolerability and not just adds complexity.

IJRTop Trump Dinner Bidders Stash Cash On Exchanges That Shut Out AmericansDylan Kresak · 3 min · 1h